Clinical trials: Cholangiocarcinoma, Intrahepatic
Intrahepatic Cholangiocarcinoma
Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma
Intrahepatic cholangiocarcinoma (ICC) is one of the common malignant tumors. Lymph node metastasis is an important factor affecting the poor prognosis of intrahepatic cholangiocarcinoma.
- Trial name
- NCT04078230
- Testing
- Extend LymphAdenectomy
- Where
- 13 sites in United States, China
- Volunteers
- 168 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Liver Cancer, Intrahepatic Cholangiocarcinoma
REGULUS: MRI-guided Adaptive SABR for Liver Cancers
Single arm unblinded study of simulation-free MRI-guided SABR with adaptive replanning in one session for treatment of patients with liver cancers
- Conditions
- Liver Cancer, Intrahepatic Cholangiocarcinoma, Liver Metastases, HCC
- Trial name
- NCT07223307
- Testing
- MRI-guided adaptive stereotactic ablative body radiotherapy (SABR)
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Stanford University
Organoids, Intrahepatic Cholangiocarcinoma
Clinical Transformation of Organoid Model to Predict the Efficacy of GC in the Treatment of Intrahepatic Cholangiocarcinoma
The clinical incidence of intrahepatic cholangiocarcinoma (ICC) is high and insidious, and the prognosis of advanced patients is poor.
- Trial name
- NCT05644743
- Testing
- gemcitabine + cisplatin
- Volunteers
- 40 people
- Sponsor
- Chengjun Sui,MD
Intrahepatic Cholangiocarcinoma, Peripheral Cholangiocarcinoma
Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)
The purpose of this study is to use both, liver pump treatment and systemic chemotherapy, to assess the effects this type of treatment has on the patient and the tumor.
- Conditions
- Intrahepatic Cholangiocarcinoma, Peripheral Cholangiocarcinoma, Cholangiolar Carcinoma, Cholangiocellular Carcinoma
- Trial name
- NCT01862315
- Testing
- Floxuridine (FUDR), dexamethasone, Gemcitabine
- Where
- 6 sites in United States
- Volunteers
- 56 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Intrahepatic Cholangiocarcinoma
Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy
Underlying disease mechanisms are fundamental for correct treatment selection and patient management in highly invasive and debilitating non-transmissible diseases.
- Trial name
- PM-CARE (NCT06375915)
- Testing
- radioembolization with Y-90, Durvalumab, Cisplatin
- Where
- 4 sites in Italy
- Volunteers
- 33 people
- Sponsor
- Francesco De Cobelli
Cholangiocarcinoma Non-resectable
DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma
The aim of this study is to the efficacy, prognosis, adverse effects, and factors for predicting therapeutic effects and clinical prognosis of combined therapy of Drug-eluting Beads-transarterial chemoembolization (DEB-TACE)…
- Trial name
- CCGLC-009 (NCT06194695)
- Testing
- drug eluting beads-transcatheter arterial chemoembolization, envatinib plus anti-PD(L)1
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Ze-yang Ding, MD
Cholangiocarcinoma Resectable
Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig in Resectable iCCA
Biliary tract cancer is a highly aggressive and heterogeneous group of gastrointestinal cancers that arise from the intra- or extrahepatic bile ducts (CCA), or the gallbladder (GBC)(1-3).
- Trial name
- NEOLANGIO (NCT06569225)
- Testing
- Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University Health Network, Toronto
Intrahepatic Cholangiocarcinoma
Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma
A randomized controlled, phase II clinical trial is designed to compare the safety and efficacy of Sintilimab combined with GEMOX ± IBI305 and GEMOX as first-line therapy in advanced intrahepatic cholangiocarcinoma.
- Trial name
- NCT05251662
- Testing
- Sintilimab, IBI305, GEMOX
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Intrahepatic Cholangiocarcinoma
Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma
This is a prospective, Two-arm, comparative, randomized, controlled phase II trial, to explore the efficacy and safety of Regorafenib and HAIC vs. FOLFOX as Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma.
- Trial name
- NCT05535647
- Testing
- Regorafenib and HAIC, FOLFOX
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Biliary Tract Neoplasms, Advanced Cancer
A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer
"Biliary tract cancer (BTC) is a rare malignancy with a poor prognosis. Most patients present with unresectable disease, and even after curative-intent resection, recurrence is common.
- Conditions
- Biliary Tract Neoplasms, Advanced Cancer, Immunotherapy
- Trial name
- NCT07269158
- Testing
- Durvalumab or Pembrolizumab, Durvalumab or Pembrolizumab + Levnatinib, Durvalumab or Pembrolizumab + Venadaparib
- Where
- South Korea
- Volunteers
- 160 people
- Sponsor
- Yonsei University
Cholangiocarcinoma
Chemotherapy Combined with Immunotherapy and Targeted Therapy in Cholangiocarcinoma
This study aims to validate the efficacy and safety of GP/GEMOX combined with PD-1/L1 inhibitors and TKI agents in patients with advanced cholangiocarcinoma through a multicenter, retrospective study to guide clinical practice.
- Trial name
- NCT06718257
- Testing
- Gemcitabine combined with cisplatin or oxaliplatin, Gemcitabine combined with cisplatin or oxaliplatin, PD-1/L1 and TKI inhibitors
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Resectable Cholangiocarcinoma, Stage IB Intrahepatic Cholangiocarcinoma AJCC v8
Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer
This phase II trial studies how well gemcitabine, cisplatin, and nab-paclitaxel work before surgery in treating participants with high-risk bile duct cancer in the liver (intrahepatic cholangiocarcinoma).
- Conditions
- Resectable Cholangiocarcinoma, Stage IB Intrahepatic Cholangiocarcinoma AJCC v8, Stage II Intrahepatic Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8
- Trial name
- NCT03579771
- Testing
- Cisplatin, Gemcitabine, Nab-paclitaxel
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Emory University
Locally Advanced Intrahepatic Cholangiocarcinoma, Oligometastatic Intrahepatic Cholangiocarcinoma
Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma
This phase I trial tests the safety and side effects of yttrium-90 (Y90) radioembolization combined with immunotherapy drugs tremelimumab and durvalumab in treating patients with intrahepatic cholangiocarcinoma (cancer of the…
- Conditions
- Locally Advanced Intrahepatic Cholangiocarcinoma, Oligometastatic Intrahepatic Cholangiocarcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
- Trial name
- NCT06058663
- Testing
- Angiography, Biopsy, Biospecimen Collection
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Mayo Clinic
ICC
Combining Chemoradiotherapy With Sintilimab in First-Line ICC
To evaluate the effectiveness and safety of GC (gemcitabine + cisplatin) and radiotherapy combined with slulimumab in the treatment of first-line intrahepatic cholangiocarcinoma patients
- Trial name
- NCT06447454
- Testing
- radiotherapy, gemcitabine + cisplatin, slulimumab
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Shanghai Zhongshan Hospital
Intrahepatic Cholangiocarcinoma (Icc)
Liver Transplantation for Unresectable Intrahepatic Colangiocarcinoma After Sustained Response to Neoadjuvant Treatments
This is single-arm, observational, academic, investigator-driven study investigating the efficacy of liver transplantation after successful and sustained downstaging/tumor control of liver-limited unresectable intrahepatic…
- Trial name
- iCOLA (NCT06862934)
- Where
- Italy
- Volunteers
- 14 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence
Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer
This is a prospective, single-arm exploratory study to evaluate the efficacy and safety of chemotherapy combined with Adebrelimab and Apatinib as the perioperative treatment in Patients With Biliary Tract Cancer.
- Trial name
- NCT06280508
- Testing
- Adebrelimab, Apatinib, Gemcitabine, cisplatin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Intrahepatic Cholangiocarcinoma
HAIC Plus Targeted Therapy and/or PD-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma
Intrahepatic cholangiocarcinoma (ICC) is associated with poor prognosis. This study aims to explore the efficacy and safety FOLFOX-HAIC in combination with targeted therapy and/or PD-1 inhibitors for patients with initially…
- Trial name
- NCT05489692
- Testing
- hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil, and leucovorin (FOLFOX)
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Sun Yat-sen University
Intrahepatic Cholangiocarcinoma (Icc)
Second-line Regimen Combined With Radiotherapy Versus Without Radiotherapy in Patients With Locally Advanced/Oligometastatic ICC After Failure of First-line Treatment：an Open-label, Randomized, Controlled Phase II Clinical Study
Second-line regimen with or without consolidative radiotherapy in patients with oligometastatic/locally advanced unresectable intrahepatic cholangiocarcinoma: an open-label, randomised, controlled study.
- Trial name
- SED-RO-ICC (NCT06946849)
- Testing
- radiotherapy, FOLFIRI or FOLFOX or Regorafenib
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Shanghai Zhongshan Hospital
Liver Metastases, Hepatocellular Carcinoma
Stereotactic Body Radiotherapy for Liver Tumors
This study will evaluate the local control rate as well as acute and late toxicity rates of stereotactic body radiotherapy for the treatment of liver metastases and unresectable primary liver tumors such as hepatocellular…
- Conditions
- Liver Metastases, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
- Trial name
- NCT01347333
- Testing
- Stereotactic body radiosurgery, Stereotactic Body Radiotherapy
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Mercy Research
Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme), Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas)
A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 as a single agent and in combination with other anti-cancer drugs in patients with advanced solid tumors and gliomas.
- Conditions
- Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme), Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas), Cohort 3a and 3b: Chondrosarcoma, Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma
- Trial name
- NCT03684811
- Testing
- FT-2102, Azacitidine, Nivolumab
- Where
- 26 sites in United States, Australia and 4 more
- Volunteers
- 93 people
- Sponsor
- Forma Therapeutics, Inc.